Vertex Stock Drops: ALYFTREK® Data Disappoints at ECFS

viernes, 6 de junio de 2025, 3:00 pm ET1 min de lectura
VERX--
Vertex, Inc. declined 1.55% in intraday trading. The company presented new data on the benefits of ALYFTREK® and other CFTR modulators at the European Cystic Fibrosis Society’s 48th European Cystic Fibrosis Conference, demonstrating positive clinical and quality of life benefits.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios